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Summary The aim of this retrospective cohort study was to investigate whether survival of patients with breast cancer has changed over the
period 1975-89. A total of 2604 women diagnosed as having invasive breast cancer at a clinical oncology unit in London were followed up for
between 5 and 20 years. Patients were divided into four groups according to menstrual status (pre or post) and the staging of cancer
(operable or inoperable). For each group, survival from diagnosis was compared between three consecutive 5-year cohorts, both with and
without adjustments made for relevant prognostic factors. No temporal patterns were found in patients with inoperable cancer, in whom the
survival rate was consistently low. Of women with operable cancers, differences were seen only among post-menopausal women, for whom
the best survival patterns were seen in patients diagnosed between 1985-89. This is probably due to tamoxifen being commonly prescribed
as adjuvant treatment for this cohort of patients. We cannot explain an apparently worse survival in the group of patients presenting in the
early 1980s compared with that observed in the late 1970s.
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Following a steady rise over the preceding two decades, the
mortality rate for breast cancer in England and Wales has shown a
downward trend in recent years (Beral et al, 1995). This may be in
part due to a number of factors such as the increase in screening
availability (Quinn and Allen, 1995), accuracy of diagnosis and
changes in the assignment of cause of death (OPCS, 1984),
changes in reproductive patterns (Hermon and Beral, 1996) and
improved treatment (Early Breast Cancer Trialists Collaborative
Group, 1992; Quinn and Allen, 1995; Hermon and Beral, 1996),
although these may not wholly explain the apparent trend. A study
in British Columbia, Canada, by Olivotto et al (1994) concluded
that survival of women with newly diagnosed breast cancer had
improved notably from 1974 to 1984, and suggested that the
increased use of adjuvant therapy in this period may have had an
important influence on this.
Both of these claims are based on national cancer mortality
statistics or cancer registry data. The aim ofthis study was to inves-
tigate the survival ofpatients treated at a single breast unit over the
period 1975-89, with reference to known prognostic indicators.
MATERIALS AND METHODS
Patients
For this study we considered patients who had been diagnosed and
treated at the Breast Unit at Guy's Hospital in London, who were
diagnosed between I January 1975 and 31 December 1989 inclu-
sive. The details of all patients were entered on a database that
contained information on the patient and the cancer. In all, 3023
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patients had been diagnosed at the Breast Unit during this period.
Patients with a pure in situ tumour or an operable invasive tumour
with unknown nodal status were excluded from the study, as were
patients who had either an unknown menstrual status or were preg-
nant or lactating. A total of2604 patients met the entry requirements
for this study, ofwhom 1437 (55.2%) had died by November 1995,
the end ofthe follow-up period for this study. Over the entire period
of the study, the definition of menstrual status was constant and
related to the patient's report of her last menstrual period. Patients
who had menstruated within the previous 6-months before diagnosis
were regarded as premenopausal, others as post-menopausal.
Staging investigations, which were constant throughout the period
of the study, were relatively limited, being confined to haematolog-
ical and biochemical screens and chest radiographs, further investi-
gations being undertaken only when indicated by abnormal results
or symptoms. Additionally, bone scintigraphy was carried out in
most patients early on in the study but, as it became clear that
positive results in patients with operable tumours were very rare
(Chaudary et al, 1983), this investigation was less commonly
performed in later years, particularly with the increasing use
of breast-conserving treatment. Follow-up remained uniform
throughout the entire period. For the first 2 years after primary
surgery, patients were seen at 3-monthly intervals, over the next 3
years at 6-monthly intervals and annually thereafter. For patients
who moved elsewhere, follow-up reports were requested each year.
In order to examine the hypothesis that survival may have
changed for patients diagnosed over the period of the study, the
patients were subdivided into three consecutive cohorts according
to the year of diagnosis: 1975-79, 1980-84 and 1985-89. We
compared survival in these three cohorts in three ways: firstly,
considering the overall (unadjusted) survival; secondly, after
allowing for patient and tumour characteristics (prognostic
factors); and, thirdly, after allowing for these characteristics in
conjunction with the patients' treatment regimen (treatment type).
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Table 1 Patient characteristics by year of diagnosis
Cohort
1975-79 1980-84 1985-89
Total number of patients 806 954 844
Total number of deaths (%) 511 (63.4) 569 (59.6) 357 (42.3)
Within five years of diagnosis (%) 258 (32.0) 323 (33.9) 259 (30.7)
(a) Prognostic factors [number (%) or median (range)]
Age (years) 55 (23-94) 56 (21-95) 57 (23-92)
Tumour size (cm) 3 (0-18) 3(0-20) 3.5 (0-16)
Stage
Node negative (stage 1) 343 (42.6) 407 (42.7) 329 (39.0)
Node positive (stage 11) 333 (41.3) 360 (37.7) 324 (38.4)
Stage 1I1 85 (10.6) 128 (13.4) 143 (16.9)
Stage IV 45 (5.6) 59 (6.2) 48 (5.7)
Histological type
Infiltrating ductal
Grade 71 (8.8) 43 (4.5) 67 (7.9)
Grade II 389 (48.3) 484 (50.7) 394 (46.7)
Grade III 218 (27.0) 272 (28.5) 268 (31.8)
Grade unknown 65 (8.1) 34 (3.6) 14 (1.7)
Other types 63 (7.8) 121 (12.7) 101 (12.0)
Hormone receptorstatus
Oestrogen receptor positive 371 (46.0) 636 (66.7) 559 (66.2)
Oestrogen receptor negative 189 (23.4) 189 (19.8) 174 (20.6)
Oestrogen receptor unknown 246 (30.5) 129 (13.5) 111 (13.2)
Progesterone receptor positive 193 (24.0) 469 (49.2) 408 (48.3)
Progesterone receptor negative 275 (34.1) 344 (36.1) 316 (37.4)
Progesterone receptor unknown 338 (41.9) 141 (14.8) 120 (14.2)
(b)Treatment given [number (%)]
None 589 (73.1) 716 (75.1) 421 (49.9)
Single-agent chemotherapy 121 (15.0) None 2 (0.2)
Combination chemotherapy 43 (5.3) 134 (14.1) 118 (14.0)
Single-agent tamoxifen 17 (2.1) 25 (2.6) 196 (23.2)
Combination tamoxifen 31 (3.9) 68 (7.1) 63 (7.5)
Endocrine (i.e. non-tamoxifen) 5 (0.6) 11 (1.2) 44 (5.2)
The prognostic factors for patients in each cohort are presented
in Table la. The size of the tumour was considered after log trans-
formation, with clinically undetectable tumours (with 'zero size')
accommodated by adding 1 to all observations. The hormone
receptor status was considered a binary variable with a cut-off
point of 10 fmol mg-'. Histological grade for invasive ductal carci-
nomas was classified as grade 1, 2 or 3, or 'unknown'; other histo-
logical types as 'other'. Stage II cancer was categorized by the
number of pathologically involved nodes. We considered three
such categories: 1-3, 4-9 or ten or more nodes.
The treatment types are presented in Table lb. These have been
grouped as (i) none; (ii) single-agent adjuvant chemotherapy; (iii)
combination primary and/or adjuvant chemotherapy; (iv) adjuvant
therapy tamoxifen; (v) tamoxifen in combination with pred-
nisolone and/or CMF; and (vi) other endocrine treatment.
Statistical analysis
Primaryanalysis
The time elapsed between diagnosis and death or date last seen
was computed as appropriate for each patient. The patients were
stratified into one of four groups according to advancement of
cancer at diagnosis (operable or inoperable) and menstrual status
(pre- or post-menopausal), with a separate analysis for each group.
The primary end point was death from any cause. Unadjusted
survival was compared between cohorts by the log-rank test, and
then survival adjusted for the prognostic factors and treatment
types was modelled by Cox proportional hazards regression.
Secondaryanalyses
Several secondary analyses were performed to investigate the
possible sensitivity of the results to certain aspects of the analysis
strategy. Firstly, instead of using death from any cause as the end
point, we repeated the analysis with deaths caused specifically
through breast cancer. The main analysis was also repeated with
different levels of hormone receptivity considered as the cut-off
point, as several have been used in the literature; we have consid-
ered 5 and 15 fmol here and report on any differences in their
effect. Thirdly, as a check on the possible impact ofthe variation in
the follow-up time between cohorts, we reanalysed the survival
times with patients still alive 10 years after diagnosis considered
censored at that time, and then with the censoring date brought
forward to 5 years after diagnosis. The Cox regression analyses
make assumptions about covariate effects that, strictly speaking,
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Table 2 Patient characteristics by analysis group
Patients with operable tumour Patients with inoperable tumour
Menstrual status Pre Post Pre Post
Total number of patients 812 1284 100 408
Total number of deaths 310 (38.2) 680 (53.0) 80 (80.0) 367 (90.0)
Within five years of diagnosis (%) 155 (19.1) 315 (24.5) 61 (61.0) 309 (75.7)
(a) Prognostic factors [number (%) or median (range)]
Tumour size (cm) 2.5 (0-10) 3 (0-16) 6 (0-19) 5.5 (0-20)
Age (years) 44 (21-67) 61 (36-88) 43 (25-53) 65 (38-95)
Stage
Node negative (stage 1) 405 (49.9) 674 (52.5) NA NA
Node positive (stage 11) 407 (50.1) 610 (47.5) NA NA
Stage Ill NA NA 87 (87.0) 269 (65.9)
Stage IV NA NA 13 (13.0) 139 (34.1)
Histological type
Infiltrating ductal
Grade 83 (10.2) 87 (6.7) 1 (1.0) 10 (2.4)
Grade II 383 (47.2) 664 (51.8) 43 (43.0) 176 (43.1)
Grade III 250 (30.8) 346 (27.0) 39 (39.0) 123 (30.2)
Grade unknown 12 (1.5) 38 (3.0) 6 (6.0) 57 (14.0)
Other types 84 (10.3) 148 (11.5) 11 (11.0) 42 (10.3)
Hormone receptorstatus
Oestrogen receptor positive 470 (57.9) 822 (64.0) 46 (46.0) 228 (55.9)
Oestrogen receptor negative 201 (24.7) 257 (20.0) 32 (32.0) 62 (15.2)
Oestrogen receptor unknown 141 (17.4) 205 (16.0) 22 (22.0) 118 (28.9)
Progesterone receptor positive 380 (46.8) 511 (39.8) 37 (37.0) 142 (34.8)
Progesterone receptor negative 262 (32.3) 513 (40.0) 36 (36.0) 124 (30.4)
Progesterone receptor unknown 170 (20.9) 260 (20.2) 27 (27.0) 142 (34.8)
(b)Treatment given [number (%)]
None 586 (7.2) 957 (74.5) 33 (33.0) 150 (36.8)
Single-agent chemotherapy 53 (6.5) 68 (5.3) None 2 (0.5)
Combination chemotherapy 123 (15.2) 63 (4.9) 47 (47.0) 62 (15.2)
Single-agent tamoxifen 9 (1.1) 195 (15.2) None 34 (8.3)
Combination tamoxifen None None 4 (4.0) 158 (38.7)
Endocrine (i.e. non-tamoxifen) 41 (5.0) 1 (0.1) 16 (16.0) 2 (0.5)
Table 3 Unadjusted death rates
Unadjusted survival percentages (with 95% Greenwood confidence intervals)
Total no. 5 years 10 yearsa
Operable patients
Premenopausal
1975-79 272 79.7 (74.3-84.0) 65.5 (59.5-78.0)
1980-84 308 83.7 (79.1-87.4) 66.8 (61.2-71.7)
1985-89 232 78.4 (72.5-83.1)
Overall 812 80.8 (78.0-83.4) 65.0 (61.5-68.3)
Post-menopausal
1975-79 404 75.0 (70.5-78.9) 52.8 (47.8-57.5)
1980-84 459 69.4 (65.0-73.4) 49.3 (44.6-53.8)
1985-89 421 82.4 (78.4-85.7)
Overall 1284 75.4 (73.0-77.7) 53.7 (50.7-56.5)
Inoperable patients
Premenopausal
1975-79 27 26.9 (11.9-44.5) 15.4 (4.8-31.5)
1980-84 38 46.0 (29.6-60.9) 24.3 (12.1-38.9)
1985-89 35 36.1 (20.6-51.8)
Overall 100 37.3 (27.8-46.8) 18.6 (11.2-27.4)
Post-menopausal
1975-79 103 18.6 (11.8-26.7) 7.8 (3.7-14.1)
1980-84 149 24.2 (17.6-31.3) 6.0 (3.0-10.6)
1985-89 156 27.5 (26.8-34.7)
Overall 408 24.1 (20.0-28.3) 8.7 (6.0-12.3)
aNo 10-year survival rates are presented for patientspresenting in theperiod 1985-89, as the follow-up time can only include those diagnosed in 1985.
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Figure 1 Overall patient survival by time cohort. A-D represent survival in each of the four subgroups by the three time cohorts, with the number of patients at
risk in each cohort noted at the foot of the graph. A Overall survival among premenopausal patients with operable cancer. B Overall survival among post-
menopausal patients with operable cancer. C Overall survival among premenopausal patients with inoperable cancer. D Overall survival among post-
menopausal patients with inoperable cancer
Table 4 Hazard ratios with 95% confidence intervals for each cohort, compared with 1980-84
Unadjusted Adjustedab
All data Ten-year follow-upc All data Ten-year follow-up
Premenopausal, operable tumours
1975-79 1.02 (0.78-1.33) 1.07 (0.81-1.42) 1.00 (0.69-1.44) 1.10 (0.74-1.62)
1985-89 1.18 (0.88-1.59) 1.21 (0.89-1.63) 1.19 (0.85-1.67) 1.24 (0.88-1.75)
Post-menopausal, operable tumours
1975-79 0.80 (0.67-0.96) 0.88 (0.73-1.07) 0.62 (0.48-0.80) 0.68 (0.51-0.90)
1985-89 0.63 (0.51-0.78) 0.66 (0.53-0.82) 0.78 (0.61-1.00) 0.79 (0.61-1.02)
Premenopausal, inoperable tumours
1975-79 1.27 (0.73-2.21) 1.40 (0.80-2.45)
1985-89 1.45 (0.86-2.46) 1.53 (0.89-2.61)
Post-menopausal, inoperable tumours
1975-79 1.11 (0.86-1.43) 1.05 (0.81-1.36) 0.69 (0.41-1.15) 0.66 (0.39-1.12)
1985-89 0.82 (0.64-1.04) 0.80 (0.63-1.02) 0.94 (0.69-1.28) 0.93 (0.68-1.27)
aAdjusted hazard ratios: relative survival taking into account patient and tumour characteristics (detailed in Table 1a) and treatment types (see Table 1b). bNo
adjusted rates are presented for premenopausal patients with inoperable cancer. The small number of patients in this subgroup restricted the modelling to the
extent where no meaningful presentation is possible. cCox proportional hazards modelling restricting follow-up times to a maximum of 10 years (see secondary
analysis section).
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extrapolate beyond the data for more recent cohorts. Finally, the
menstrual status marker was substituted for an age cut-offpoint of
50 years to assess comparability in the case for which the
menstrual status is unavailable.
the previous approach to modelling was inappropriate. Instead,
forwards stepwise regression was performed with the cohort term
included in all cases. However, there was no evidence that adjusted
survival changed over this period.
RESULTS
Tables I and 2 summarize the patient characteristics in relation to
cohort and analysis group. There appears a consistent trend in the
stage at presentation, with patients from the 1970s having less
advanced cancer than those presenting in the 1980s, a trend which
was still apparent after taking into account patients with operable
cancer but unknown nodal status. The increase in tamoxifen treat-
ment in the 1980s may also be seen here, with most of the treated
patients receiving this in the years 1985-89.
The results of Cox regression analyses are considered in detail
below for the four subgroups individually, with Kaplan-Meier
survival curves shown in Figure IA-D. Table 3 shows the
Kaplan-Meier estimated survival percentages for 5 and 10 years
after diagnosis for each cohort.
Survival among patients with operable tumours
Premenopausal patients
No significant cohort effects were found in premenopausal
patients, either before or after allowing for the prognostic factors in
Table la. The tumour size, nodal status and grade were all signifi-
cantly, and negatively, associated with survival as expected, with
older women having a reduced risk of death. Allowing for treat-
ment, patients on a combination chemotherapy treatment regimen
had a better survival than untreated patients (hazard ratio 0.39,
95% confidence interval 0.28-0.57). No effect was seen for the
other treatments (single chemotherapy and endocrine treatment).
Post-menopausal patients
In post-menopausal women with operable tumours a large signifi-
cant difference in survival was apparent between the three cohorts
(log-rank chi-squared statistic 18.95, d.f. = 2, P = 0.0001). Patients
diagnosed in the period 1985-89 survived longer than those in
1980-84 (Cox proportional hazards model hazard ratio 0.63, 95%
CI 0.51-0.78, P < 0.001), as did the 1975-79 cohort (hazard ratio
0.80, 95% CI 0.67-0.96, P = 0.015). Performing Cox regression
on the data with the prognostic factors included in the model did
not explain the differences, although the best adjusted survival rate
was found in the 1975-79 cohort. Larger tumours, high grade, high
nodal involvement and older age at diagnosis were all associated
with a decreased survival time.
Adding treatment type to the model shrank the cohort effect for
1985-89 (hazard ratio 0.78, 95% CI 0.61-1.00, P=0.05) and
increased further the 1975-79 cohort survival effect (hazard ratio
0.62, 95% CI 0.48-0.80, P < 0.001). In particular, patients
receiving tamoxifen fared better than untreated patients (hazard
ratio 0.60, 95% CI 0.44-0.83, P = 0.002).
Survival among patients with inoperable tumours
Premenopausal patients
For premenopausal patients there was little change in survival
between the three cohorts (log-rank chi-squared statistic 1.26,
d.f. = 2, P = 0.380) with the best survival appearing in the early
1980s. As there were only 100 women in this category, applying
Post-menopausal patients
For post-menopausal women there was slight evidence of an
improvement in survival in recent years, with the most recent cohort
having a better survival than the preceding two (log-rank chi-
squared statistic 5.33, d.f. = 2, P = 0.070). Adjustment forprognostic
factors appeared to account for this, however, with the presence of
metastatic cancer being by far the most prognostic. Allowing for the
treatment given to the patient did not improve the model.
Secondary analyses
Repeating the analysis using death as a result of breast cancer as
the end point gave very similar results, especially for patients with
inoperable tumours, when the death was directly attributable to
breast cancer in 433 cases, 96.9% of the total deaths. Among
patients with operable cancer, the effect of prognostic factors was
amplified, with the earlier findings regarding survival by cohort
unaltered.
Similarly, moving the cut-off point for oestrogen and proges-
terone receptivity to either 5 fmol or 15 fmol made little difference
to the results. There was the added complication with these vari-
ables that many patients had no oestrogen receptor (ER) and/or
progesterone receptor (PR) status recorded, and so additional
modelling was performed with ER and PR entered in the absence
ofeach other and then both excluded. Again, the basic results were
the same.
Censoring all survival times at 10 years produced results similar
to those obtained using the full data, especially for patients with
inoperable cancer when there were few long-term survivors. Among
post-menopausal patients with operable cancer, the revised unad-
justed hazard ratio for 1975-79 in relation to 1980-84 was 0.88
(95% CI 0.73-1.07, P = 0.19), with the 1985-89 cohort effect
almost unchanged. Adjusting forprognostic variables still gave indi-
cation of a cohort effect, with revised hazard ratios reasonably close
to the values obtained with the full data, and the effect oftamoxifen
on survival was still important. Table 4 gives a summary of these
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Figure 2 Use of tamoxifen among post-menopausal patients with operable
tumours
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findings. Censoring further at 5 years still showed a difference in
survival between the third cohort and the second forthis group, both
unadjusted and adjusted. The loss of statistical power to detect
differences is ofcourse a consideration here.
Stratifying by age as opposed to by menstrual status would lead
to the misclassification of 218 ofthe 2604 patients, most of whom
had reached 50 years of age but had not reached the meplopause.
Reanalysis of the data using age to stratify in place of menstrual
status gave results that were again very similar.
DISCUSSION
A study by Olivotto et al (1994) in British Columbia, Canada,
found an increase in survival among women diagnosed as having
breast cancer after the age of50 in 1984 compared with their coun-
terparts diagnosed 10 years earlier, and also a similar improvement
among women of 50 years or under. However, the patient records
used were described by the investigators as 'minimal', and did not
include the stage ofcancer. The findings were put down to a wider
uptake ofadjuvant systemic therapy over this period, as the health
policy introduced in 1981 offered 'high risk' post-menopausal
patients adjuvant tamoxifen.
The only significant time trends in survival we have identified
appear to be restricted to post-menopausal patients with operable
tumours, for which there is quite strong evidence to suggest that
survival of patients presenting in the early 1980s was worse than
that found either in preceding or succeeding cohorts. Much of the
improved survival in later years may be due in particular to the
increased use of tamoxifen as adjuvant therapy. The number of
patients using tamoxifen increased dramatically towards the end of
the 1980s (see Figure 2). Only after allowing for treatment did the
apparent cohort difference reduce, although there were still
marked disparities. The differences between cohorts are not
explained by the information available here, but do not seem to be
due to the difference in follow-up time.
Other than in this subgroup there is no evidence to suggest that
survival varied over the period 1975-89. The increase in use of
tamoxifen did not result in any notable change in the survivorship
of patients with inoperable tumours, but encouragingly was asso-
ciated with an improved survival among women with operable
tumours receiving it as adjuvant treatment. On the other hand,
however, the stage ofcancer at diagnosis apparently changed over
the period 1975-89, with the proportions ofpatients being referred
to the Unit in recent years having more advanced tumours than
previously. This is in spite of the increasing numbers of women
who undergo breast screening programmes designed specifically
to diagnose cancer at an earlier stage. Although a possible expla-
nation for this trend is changing referral practices, with better
prognosis cases having been withheld from the unit, we have no
evidence of this being the case. Although stage migration too
could be suggested as being an influential factor, the number of
post-menopausal patients diagnosed as having an inoperable
cancer increased in an approximately linear fashion over the
period of the study, as opposed to survival, which had a 'U-
shaped' relationship with the cohort. Further, the procedure for
defining the stage of the patients remained constant over the
period of this study. Therefore, stage migration could not be a
contributing factor in the trends seen in stage distribution and
hence survival.
The improved survival in recent years among older patients
with operable tumours is consistent with the findings ofOlivotto et
al (1994). There appears to be good reason to presume that adju-
vant tamoxifen benefited patients attending the Guys breast unit.
However, we are unable to explain why survival was worse in the
period 1980-84 than in the preceding cohort. The 1984 revision of
the ICD interpretation resulted in an increase in the number of
deaths recorded primarily as a result of breast cancer, with these
changes affecting in the main deaths among post-menopausal
women (OPCS, 1984), but these findings are the same when
considering either breast cancer-specific death or death through
any cause. No clear time trends were seen in the other three
groups.
The suggestion by Beral et al (1995) that mortality as a result of
breast cancer was falling in the early 1990s may be supported by
this study. However, in the figures quoted, the downward trend
existed in both age bands, with the greatest decrease in mortality
being among women under the age of 50. Here, we have found an
apparent improvement in survival among older, but not, with
certainty, in younger women.
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